Compare AbbVie Inc (ABBV) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Fiverr International Ltd — how do they compare? AbbVie Inc trades at $248.76 (market cap $441.94B), while Fiverr International Ltd trades at $8.73 (market cap $314.57M). The key difference: AbbVie Inc is far larger — about 1404.9× Fiverr International Ltd's market cap, and AbbVie Inc pays a 2.77% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| ABBV | FVRR | |
|---|---|---|
Market Cap | $441.94B | $314.57M |
Sector | Health | Industrials |
52-Week High | $263.58 | $26.67 |
52-Week Low | $197.38 | $8.75 |
Enterprise Value | $506.19B | $66.95M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.
Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.
Fiverr International (FVRR) trades at $8.66, down 4.73% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation ratios with a P/E of 10.8 and P/S of 0.77, but faces headwinds from AI disruption compressing demand for freelance services. Revenue declined to $97.8 million in Q2 2026 (MarketBeat, July 29, 2026), contributing to a lowered full-year outlook.
The investment outlook is cautious. While valuations appear cheap and the company maintains a strong gross margin of 82%, significant risks from competitive AI technologies and recent execution challenges temper near-term optimism. Analyst consensus leans Hold with a $10.70 price target, suggesting limited upside from current levels amid transitional pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
